WAYNE, Pa.--(BUSINESS WIRE)--Oct. 10, 2016--
Teleflex Incorporated (NYSE:TFX), a leading global provider of medical
devices for critical care and surgery, has announced it has received FDA
510(k) clearance to market its Arrow® JACC with Chlorag+ard®
Technology and TightTrack™ tunneler.
Arrow JACC with Chlorag+ard Technology is a long-term,
tunneled, small french size antithrombogenic1 and
antimicrobial2 central venous catheter designed to meet the
needs of patients throughout their course of therapy or illness. The
catheter is also designed for use with high-pressure injection for
diagnostic studies. The Arrow JACC with Chlorag+ard
Technology protects against catheter occlusion3, phlebitis4,
and intimal hyperplasia4 for up to 30 days. The Arrow JACC
with Chlorag+ard Technology will enable caregivers to
effectively and economically preserve vessel access, and care for
millions of end stage renal disease patients.
“At Teleflex, we are committed to providing the right line for the right
patient at the right time™,” said Jay White, President of the Vascular
Division. “We are proud to add the tunneled Arrow JACC to our line of
vascular access products. By providing an antithromogenic1 and
antimicrobial2 catheter that protects against catheter
occlusion3, we are offering a technology that no one else
can. This is especially important in patients with end stage renal
disease where vessel health and preservation is essential to provide a
future dialysis vascular access5.”
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®,
Rusch® and Weck® – trusted brands united by a common sense of purpose.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
|
|
|
|
|
1.
|
|
Data on file. AS compared to uncoated catheters, intravascular
ovine model inoculated with Staph aureus. No correlation between in
vitro/in vivo testing methods and clinical outcomes have
currently been ascertained.
|
|
2.
|
|
In vitro data on file 2010. No correlation between in
vitro / in vivo testing methods and clinical outcomes have
currently been ascertained.
|
|
3.
|
|
Occlusion - As compared to uncoated PICCs, in vitro model
measuring flush pressure post exposure to human blood. No
correlation between in vitro / in vivo testing methods and
clinical outcomes have currently been ascertained.
|
|
4.
|
|
Phlebitis and Intimal Hyperplasia - As compared to uncoated PICCs,
intravascular ovine model. No correlation between in vitro / in vivo
testing methods and clinical outcomes have currently been
ascertained.
|
|
5.
|
|
KDOQI Guidelines 2006.
|
|
|
|
|
KDOQI is a trademark or registered trademark of the National Kidney
Foundation, Inc.
Teleflex, Arrow, Chlorag+ard, and the right
line, right patient, right time are trademarks or registered trademarks
of Teleflex Incorporated or its affiliates, in the U.S. and/or other
counties. All other trademarks are trademarks of their respective owners.
©
2016 Teleflex Incorporated. All rights reserved. MC-002423
View source version on businesswire.com: http://www.businesswire.com/news/home/20161010005015/en/
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836